199 related articles for article (PubMed ID: 36753540)
1. Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.
Danielli SG; Porpiglia E; De Micheli AJ; Navarro N; Zellinger MJ; Bechtold I; Kisele S; Volken L; Marques JG; Kasper S; Bode PK; Henssen AG; Gürgen D; Delattre O; Surdez D; Roma J; Bühlmann P; Blau HM; Wachtel M; Schäfer BW
Sci Adv; 2023 Feb; 9(6):eade9238. PubMed ID: 36753540
[TBL] [Abstract][Full Text] [Related]
2. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
[TBL] [Abstract][Full Text] [Related]
3. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.
Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M
Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345
[TBL] [Abstract][Full Text] [Related]
4. Refractory alveolar rhabdomyosarcoma in an 11-year-old male.
Ricker CA; Woods AD; Simonson W; Lathara M; Srinivasa G; Rudzinski ER; Mansoor A; Irwin RG; Keller C; Berlow NE
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33436392
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
6. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
8. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.
Bergantin E; Quarta C; Nanni C; Fanti S; Pession A; Cantelli-Forti G; Tonelli R; Hrelia P
Cancer Biol Ther; 2014 Sep; 15(9):1219-25. PubMed ID: 24971463
[TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
11. Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.
Granados VA; Avirneni-Vadlamudi U; Dalal P; Scarborough SR; Galindo KA; Mahajan P; Galindo RL
Cancer Res; 2019 Sep; 79(18):4585-4591. PubMed ID: 31331911
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma.
Kikuchi K; Soundararajan A; Zarzabal LA; Weems CR; Nelon LD; Hampton ST; Michalek JE; Rubin BP; Fields AP; Keller C
Oncogene; 2013 Jan; 32(3):286-95. PubMed ID: 22349825
[TBL] [Abstract][Full Text] [Related]
14. Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma.
Wei Y; Qin Q; Yan C; Hayes MN; Garcia SP; Xi H; Do D; Jin AH; Eng TC; McCarthy KM; Adhikari A; Onozato ML; Spentzos D; Neilsen GP; Iafrate AJ; Wexler LH; Pyle AD; Suvà ML; Dela Cruz F; Pinello L; Langenau DM
Nat Cancer; 2022 Aug; 3(8):961-975. PubMed ID: 35982179
[TBL] [Abstract][Full Text] [Related]
15. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1.
Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Ono T; Toki S; Kobayashi E; Arakawa A; Sugiyama M; Yoshida A; Kawai A; Kondo T
Hum Cell; 2020 Oct; 33(4):1311-1320. PubMed ID: 32715445
[TBL] [Abstract][Full Text] [Related]
18. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
Saini M; Verma A; Mathew SJ
Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
[TBL] [Abstract][Full Text] [Related]
19. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
Bois PR; Izeradjene K; Houghton PJ; Cleveland JL; Houghton JA; Grosveld GC
J Cell Biol; 2005 Sep; 170(6):903-12. PubMed ID: 16157701
[TBL] [Abstract][Full Text] [Related]
20. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]